drugset
drugset / Trial / NCT04413227

A Phase Ib Study With Pegylated Recombinant Human Endostatin in Advanced / Metastatic NSCLC or Other Solid Tumors

NCT04413227 ↗

Phase 1 Unknown 30 enrolled Jiangsu Simcere Pharmaceutical Co., Ltd.
NaSingle-groupOpen-labelTreatment

Summary

The primary purpose of this study is to examine the safety, tolerability and pharmacokinetics of PEG-ENDO in combination with docetaxel in subjects previously treated or untreated (standard therapy is not suitable or without standard therapy) for advanced or metatatic non-small cell lung cancer (NSCLC) or other solid tumors.

Timeline

Start
2020-04-02
Primary completion
2021-05-31
Completion
2021-09-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Pegylated Recombinant Human Endostatin Unknown 1 mg/kg —
Subject Pegylated Recombinant Human Endostatin Unknown 2 mg/kg —
Subject Pegylated Recombinant Human Endostatin Unknown 4 mg/kg —
Subject Pegylated Recombinant Human Endostatin Unknown 6 mg/kg —
Subject Pegylated Recombinant Human Endostatin Unknown 8 mg/kg —
Background Docetaxel Small molecule 75 mg/m2 —

Indications

non-small cell lung carcinoma